Business
Palatin to Begin Trading on Nasdaq Stock Exchange
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today announced that its common stock has been approved for listing on the Nasdaq Capital Market and that the Company will transfer its stock exchange listing to Nasdaq from the NYSE American.
About this update from Palatin Technologies, Inc.
[{"type":"text","content":"PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today announced that its common stock has been approved for listing on the Nasdaq Capital Market and that the Company will transfer its stock exchange listing to Nasdaq from the NYSE American.","length":427,"tagName":"p"},{"type":"image","alt":"Palatin Technologies, Inc.","displaySize":"","headline":null,"caption":"Palatin Technologies, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":345,"url":"https://media.zenfs.com/en/prnewswire.com/965a03f88317259fbf5e1a6eed8134bc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/imMaiEtxOJVEZdtqaUOCzA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTYwOA--/https://media.zenfs.com/en/prnewswire.com/965a03f88317259fbf5e1a6eed8134bc","width":400,"height":345},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/uJ21Kss64UMkBiGyjco1tg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTU1Mg--/https://media.zenfs.com/en/prnewswire.com/965a03f88317259fbf5e1a6eed8134bc","width":400,"height":345}},"href":"https://mma.prnewswire.com/media/464561/Palatin_Technologies_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Company expects to begin trading as a Nasdaq-listed company on May 29, 2026, and will continue to trade under the symbol "PTN." Palatin's common stock will continue to trade on the NYSE American until the market close on May 28, 2026.","length":252,"tagName":"p"},{"type":"text","content":""We are pleased to announce our listing on the Nasdaq Capital Market and to join a community of leading biotechnology companies," said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies. "We believe the move to Nasdaq will improve the visibility of our common stock, enhance trading liquidity in our shares, and provide us with greater exposure to institutional investors."","length":423,"tagName":"p"},{"type":"text","content":"Palatin is advancing selective MC4R-based obesity programs targeting rare obesity disorders linked to the MC4R pathway, including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome, with a focus on improved tolerability and ...